Amarin Corporation Announces Research Evaluating VASCEPA/VAZKEPA And Subgroups From The REDUCE-IT Landmark Outcomes Trial To Be Presented At The European Society Of Cardiology Congress
Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV)
Amarin Still Suspends FY22 Guidance On Generic Challenges
Amarin Corporation plc (NASDAQ:AMRN) continues suspending 2022 revenue guidance citing the ongoing global impact of COVID-19, the uncertainty resulting from the…
‘New data might have led to a different result for Amarin fish oil drug, FDA panelists say’ -STAT News
https://www.statnews.com/2022/07/18/new-data-might-have-led-to-a-different-result-for-amarin-fish-oil-drug-fda-panelists-say/
Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
Amarin Received Positive Recommendation from UK National Institute for Health and Care Excellence for Reimbursement of VAZKEPA
Amarin Corporation plc (NASDAQ: AMRN) today announces that the UK's National Institute for Health and Care Excellence (NICE) is recommending icosapent ethyl (marketed under the brand name VAZKEPA®) for reimbursement and use across the National Health Service (NHS) in England and Wales to reduce the risk of cardiovascular
Goldman Sachs Maintains Sell on Amarin Corp, Lowers Price Target to $1.5
Goldman Sachs maintains Amarin Corp (NASDAQ:AMRN) with a Sell and lowers the price target from $1.75 to $1.5.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.